Aytu BioPharma Reports Fiscal 2026 Third Quarter Operational and Financial Results
Rhea-AI Summary
Aytu BioPharma (Nasdaq: AYTU) reported fiscal 2026 Q3 net revenue of $12.4 million, down from $18.5 million a year earlier, and a net loss of $5.6 million. Adjusted EBITDA was $(2.8) million.
EXXUA generated $2.4 million net revenue in its early launch, with more than 1,300 prescriptions from over 450 prescribers and over 3,200 units sold. ADHD and Pediatric portfolio revenues declined to $9.1 million and $0.9 million, respectively.
Gross profit was $7.6 million (61% margin). Cash was $26.7 million at March 31, 2026. A warrant amendment reduced derivative warrant liabilities by $26.4 million, increasing stockholders’ equity to $35.1 million.
AI-generated analysis. Not financial advice.
Positive
- EXXUA generated $2.4 million net revenue in its first launch quarter
- More than 1,300 EXXUA prescriptions from over 450 unique prescribers
- Over 3,200 EXXUA units sold through channel partners in Q3 fiscal 2026
- ADHD Portfolio reported $9.1 million net revenue and is described as profitable
- Cash and cash equivalents of $26.7 million at March 31, 2026
- Derivative warrant liabilities reduced by $26.4 million, equity up to $35.1 million
Negative
- Total net revenue declined to $12.4 million from $18.5 million year over year
- ADHD Portfolio revenue fell to $9.1 million from $15.4 million
- Pediatric Portfolio revenue decreased to $0.9 million from $3.1 million
- Gross margin decreased to 61% from 69% in the prior-year quarter
- Net loss of $5.6 million versus prior-year net income of $4.0 million
- Adjusted EBITDA declined to $(2.8) million from $3.9 million
- Cash declined to $26.7 million from $31.0 million since June 30, 2025
Key Figures
Market Reality Check
Peers on Argus
AYTU fell 5.74% while peers were mixed: TLPH -1.55%, IXHL -10.55% versus GELS +6.25%, FLGC +5.29%, TXMD +1.04%. The divergence suggests a stock-specific reaction to AYTU’s earnings.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 03 | Quarterly earnings | Negative | -10.3% | Weaker Q2 2026 results with net loss and warrant liability drag. |
| Nov 13 | Quarterly earnings | Positive | +1.5% | Q1 2026 profit, solid revenue and cash ahead of EXXUA launch. |
| Sep 23 | Annual & Q4 results | Negative | -17.9% | Fiscal 2025 net loss despite modest revenue growth and EXXUA plans. |
| May 14 | Quarterly earnings | Positive | +91.8% | Q3 2025 strong revenue growth and return to profitability. |
| Feb 12 | Quarterly earnings | Positive | -0.7% | Q2 2025 net income and EBITDA improvement met with slight share decline. |
Earnings have historically produced sharp moves, often negative when losses or warrant impacts dominate.
Over the last several earnings cycles, Aytu has transitioned from an ADHD- and pediatric-focused model toward EXXUA-driven CNS growth. Prior reports highlighted fiscal 2025 net revenue of $66.4M with a $13.6M net loss, followed by Q1–Q2 fiscal 2026 results showing declining legacy portfolio revenue, launch investment in EXXUA, and growing warrant-related non‑cash swings. Today’s Q3 fiscal 2026 update continues that pattern: EXXUA ramps while ADHD and pediatric revenues contract, and derivative warrant accounting remains a key driver of reported net income or loss.
Historical Comparison
Past earnings headlines moved AYTU an average of ±12.87%. Today’s -5.74% reaction to Q3 fiscal 2026 results falls within that historical volatility range.
Earnings releases show a shift from legacy ADHD/pediatric profitability in fiscal 2025 toward EXXUA-centric growth in fiscal 2026, with launch spending and warrant accounting driving recent losses.
Market Pulse Summary
This announcement highlights Aytu’s fiscal 2026 Q3 transition: EXXUA generated $2.4M in net revenue while total net revenue fell to $12.4M as ADHD and pediatric portfolios declined. Profitability weakened, with a net loss of $5.6M, gross margin of 61%, and adjusted EBITDA of $(2.8)M. Cash of $26.7M and higher operating expenses reflect ongoing launch investments. Investors may track EXXUA’s growth, legacy portfolio stability, warrant-impacted earnings, and cash trends in upcoming quarters.
Key Terms
adjusted ebitda financial
derivative warrant liability financial
prefunded warrants financial
gross-to-net financial
AI-generated analysis. Not financial advice.
EXXUA -- with only a partial quarter of full sales force support -- contributed
Total net revenue of
Adjusted EBITDA1 of
Company to host conference call and webcast today, May 13, 2026, at 4:30 p.m. Eastern time
DENVER, CO / ACCESS Newswire / May 13, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced operational and financial results for the fiscal 2026 third quarter.
Q3 Fiscal 2026 Highlights
Net revenue of
$12.4 million versus$18.5 million in Q3 fiscal 2025.EXXUA net revenue was
$2.4 million during Q3 fiscal 2026. EXXUA was only made commercially available in mid-December 2025, and more formally launched in mid-January 2026 following the completion of sales force training highlighting strong adoption in the initial weeks of the full launch.ADHD Portfolio, which consists of attention deficit hyperactivity disorder ("ADHD") products, net revenue was
$9.1 million versus$15.4 million in Q3 fiscal 2025. The change in net revenue is primarily due to a transition of sales force prioritization toward EXXUA and the recent introduction of generic competition.Pediatric Portfolio, which consists of a line of legacy products, net revenue was
$0.9 million versus$3.1 million in Q3 fiscal 2025.Net loss of
$5.6 million included a$1.3 million derivative warrant liability loss primarily due to the increase in the Company's stock price, compared to net income of$4.0 million in Q3 fiscal 2025, which included a$2.3 million derivative warrant liability gain.Adjusted EBITDA was
$(2.8) million compared to$3.9 million in Q3 fiscal 2025. During Q3 fiscal 2026, the Company made planned investments towards the launch of EXXUA.Cash and cash equivalents were
$26.7 million at March 31, 2026.
Management Discussion
"Although we remain in the very early stages of the EXXUA launch, the initial traction we are seeing is highly encouraging," commented Josh Disbrow, Chief Executive Officer of Aytu. "Since the formal launch in mid-January, we have seen strong month-over-month growth, with more than 1,300 prescriptions written in the quarter by more than 450 unique prescribers. Importantly, the growth we are seeing in titration packs, together with early refill activity, reinforces our belief that EXXUA is beginning to have a meaningful impact for patients and that prescribers are increasingly recognizing its differentiated role in the treatment of MDD. We are also pleased with the execution across our channel partners, as sales of more than 3,200 units demonstrate their preparedness to support the compounding growth trajectory we anticipate as awareness, access and utilization continues to expand. While the first few months of any launch naturally include noise as coverage, gross-to-net dynamics and pharmacy ordering and prescribing patterns settle, the trends we are seeing are quite positive. Overall, we are very pleased with the launch fundamentals to date and remain focused on driving disciplined, efficient commercial execution as we work to build EXXUA into an important treatment option for the millions of Americans living with major depressive disorder."
"Our legacy business, including our ADHD and Pediatrics portfolios, continue to provide an important foundation for Aytu as we transition and prioritize resources behind the high-growth EXXUA opportunity," Disbrow continued. "As expected, the decrease in ADHD Portfolio net revenue during the quarter was primarily attributable to that strategic transition of sales force focus toward EXXUA, which started late last summer, as well as the recent introduction of generic competition for Adzenys XR-ODT®. That said, we continue to believe our ADHD Portfolio will remain a meaningful contributor moving forward and given the level of commercial support currently behind the portfolio, our ADHD Portfolio remains highly profitable on a standalone basis and continues to demonstrate the durability of these brands and the attractive economics of our commercial platform. Our Pediatric Portfolio net revenue decrease is attributable primarily to payor changes that have impacted prescribing and an increase in returns. As we continue to execute the EXXUA commercialization plans, we remain focused on balancing disciplined investment in our highest-growth opportunity with continued profitability and cash generation from our legacy operations."
"Looking ahead, we are extremely excited by EXXUA's unique and transformational opportunity, supported by a large
Net Revenue by Product Portfolio
Three Months Ended | ||||||||
March 31, | ||||||||
2026 | 2025 | |||||||
(in thousands) | ||||||||
EXXUA | $ | 2,397 | $ | - | ||||
ADHD Portfolio | 9,093 | 15,389 | ||||||
Pediatric Portfolio | 921 | 3,059 | ||||||
Other* | - | 4 | ||||||
Total net revenue | $ | 12,411 | $ | 18,452 | ||||
____________________
* Other includes discontinued or deprioritized products.
Q3 Fiscal 2026 Financial Results
Net revenue for the third quarter of fiscal 2026 was
EXXUA net revenue was
The ADHD Portfolio net revenue was
The Pediatric Portfolio net revenue was
Gross profit was
Operating expenses, excluding amortization of intangible assets, were
Net loss during the third quarter of fiscal 2026 was
Adjusted EBITDA was
As previously announced, on March 31, 2026, the Company amended and restated certain warrants, which resolved the accounting ambiguity that previously required these warrants to be classified as liabilities rather than equity. As a result, the Company reduced its derivative warrant liabilities by
As of March 31, 2026, combining both equity classified prefunded warrants and issued and outstanding common shares, there were 19.5 million shares utilized for calculating the basic weighted-average shares outstanding for earnings per share purposes.
Cash and cash equivalents were
Conference Call Details
Date and Time: Wednesday, May 13, 2026, at 4:30 p.m. Eastern time.
Call-in Information: Interested parties can access the conference call by dialing (888) 506-0062 for United States callers or +1 (973) 528-0011 for international callers and using the participant access code 273453.
Webcast Information: The webcast will be accessible live and archived at https://www.webcaster5.com/Webcast/Page/2142/53861, and accessible on the Investors section of the Company's website at https://investors.aytubio.com/ under Events & Presentations.
Replay: A teleconference replay of the call will be available until May 27, 2026, at (877) 481-4010 for United States callers or +1 (919) 882-2331 for international callers and using replay access code 53861.
About Aytu BioPharma
Aytu is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. The Company's prescription products include EXXUA™ (gepirone) extended-release tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of major depressive disorder (MDD), and treatments for attention deficit-hyperactivity disorder (ADHD). Aytu is committed to delivering the Company's medications through best-in-class patient access programs that help to enable optimal patient outcomes. For more information, please visit aytubio.com or follow us on LinkedIn.
About EXXUA
EXXUA is a novel oral selective serotonin 5-HT1A receptor agonist indicated for the treatment of major depressive disorder (MDD) in adults.
IMPORTANT SAFETY INFORMATION
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS
Antidepressants increase the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors. EXXUA is not approved for use in pediatric patients.
INDICATIONS AND USAGE
EXXUA is indicated for the treatment of major depressive disorder (MDD) in adults.
DOSAGE AND ADMINISTRATION
Important Recommendations Prior to Initiating and During Treatment with EXXUA
Electrocardiogram and Electrolyte Monitoring
Correct electrolyte abnormalities prior to initiating EXXUA. In patients with electrolyte abnormalities, or who are receiving diuretics or glucocorticoids, or who have a history of hypokalemia or hypomagnesemia, also monitor electrolytes during dose titration and periodically during treatment with EXXUA.
Perform an electrocardiogram (ECG) prior to initiating EXXUA, during dosage titration, and periodically during treatment. Do not initiate EXXUA if QTc is > 450 msec at baseline. Monitor ECGs more frequently if EXXUA is used:
concomitantly with drugs known to prolong the QT interval
in patients who develop QTc ≥ 450 msec during treatment
in patients with a significant risk of developing torsade de pointes
Do not escalate the EXXUA dosage if the QTcF is > 450 msec.
Bipolar Disorder, Mania, and Hypomania Screening
Screen patients for a personal or family history of bipolar disorder, mania, or hypomania prior to initiating treatment with EXXUA.
Important Administration Instructions
Take EXXUA orally with food at approximately the same time each day. Swallow tablets whole. Do not split, crush, or chew EXXUA.
Recommended Dosage
The recommended starting dosage of EXXUA is 18.2 mg once daily. Based on clinical response and tolerability, the dosage may be increased to 36.3 mg orally once daily on Day 4 and further titrated to 54.5 mg orally once daily after Day 7 and to 72.6 mg orally once daily after an additional week. The maximum recommended daily dosage of EXXUA is 72.6 mg once daily.
Dosage Recommendations in Geriatric Patients
The recommended starting dosage of EXXUA in geriatric patients is 18.2 mg orally once daily. Based on clinical response and tolerability, the dosage may be increased to maximum recommended dosage of 36.3 mg orally once daily after Day 7.
Recommended Dosage in Patients with Renal Impairment
The recommended starting dosage of EXXUA in patients with creatinine clearance < 50 mL/min is 18.2 mg orally once daily. Based on clinical response and tolerability, the dosage may be increased to the maximum recommended dosage of 36.3 mg orally once daily after Day 7. The recommended dosage in patients with creatinine clearance ≥ 50 mL/min is the same as in patients with normal renal function.
Recommended Dosage in Patients with Hepatic Impairment
The recommended starting dose of EXXUA in patients with moderate (Child-Pugh B) hepatic impairment is 18.2 mg once daily. Based on clinical response and tolerability, the dosage may be increased to the maximum recommended dosage of 36.3 mg orally once daily after Day 7. EXXUA is contraindicated in patients with severe (Child-Pugh C) hepatic impairment. The recommended dosage in patients with mild (Child-Pugh A) hepatic impairment is the same as patients with normal hepatic function.
Dosage Modifications for Concomitant Use with CYP3A4 Inhibitors
Reduce the EXXUA dose by
Switching a Patient to or from a Monoamine Oxidase Inhibitor (MAOI) Antidepressant
At least 14 days must elapse between discontinuation of an MAOI intended to treat depression and initiation of therapy with EXXUA. Conversely, at least 14 days must be allowed after stopping EXXUA before starting an MAOI antidepressant.
CONTRAINDICATIONS
EXXUA is contraindicated in patients:
with known hypersensitivity to gepirone or components of EXXUA.
with prolonged QTc interval > 450 msec at baseline.
with congenital long QT syndrome.
receiving concomitant strong CYP3A4 inhibitors.
with severe hepatic impairment.
taking, or within 14 days of stopping, MAOIs due to the risk of serious and possibly fatal drug interactions, including hypertensive crisis and serotonin syndrome. Starting EXXUA in a patient treated with reversible MAOIs such as linezolid or intravenous methylene blue is also contraindicated.
WARNINGS AND PRECAUTIONS
Suicidal Thoughts and Behaviors in Adolescents and Young Adults
In pooled analyses of placebo-controlled trials of antidepressant drugs (SSRIs and other antidepressant classes) that included approximately 77,000 adult patients, and 4,500 pediatric patients, the incidence of suicidal thoughts and behaviors in antidepressant-treated patients aged 24 years and younger was greater than in placebo-treated patients.
There was considerable variation in risk of suicidal thoughts and behaviors among drugs, but there was an increased risk identified in young patients for most drugs studied. There were differences in absolute risk of suicidal thoughts and behaviors across the different indications, with the highest incidence in patients with MDD.
*EXXUA is not approved for use in pediatric patients.
Monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy, and at times of dosage changes. Counsel family members or caregivers of patients to monitor for changes in behavior and to alert the healthcare provider. Consider changing the therapeutic regimen, including possibly discontinuing EXXUA, in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.
QT Prolongation
EXXUA prolongs the QTc interval.
EXXUA is contraindicated in patients with congenital long QT syndrome and in patients with severe hepatic impairment or in patients receiving concomitant strong CYP3A4 inhibitors as they increase EXXUA plasma concentrations.
Do not initiate EXXUA if QTc is > 450 msec at baseline.
Correct electrolyte abnormalities prior to EXXUA initiation. In patients with electrolyte abnormalities, who are receiving diuretics or glucocorticoids, or have a history or hypokalemia or hypomagnesemia, also monitor electrolytes during dose titration and periodically during treatment with EXXUA.
Perform an ECG prior to EXXUA initiation, during dosage titration, and periodically during treatment. Monitor patients with ECGs more frequently:
If EXXUA is used concomitantly with drugs known to prolong the QT interval.
In patients who develop QTc ≥ 450 msec during treatment with EXXUA. Do not escalate the EXXUA dosage if QTcF is > 450 msec.
In patients with a significant risk of developing torsade de pointes, including those with uncontrolled or significant cardiac disease, recent myocardial infarction, heart failure, unstable angina, bradyarrhythmias, uncontrolled hypertension, high degree atrioventricular block, severe aortic stenosis, or uncontrolled hypothyroidism.
Reduce the EXXUA dosage when used concomitantly with moderate CYP3A4 inhibitors, as they may increase EXXUA concentrations.
Serotonin Syndrome
Concomitant use of EXXUA with SSRIs or tricyclic antidepressants may cause serotonin syndrome, a potentially life-threatening condition with changes including altered mental status, hypertension, restlessness, myoclonus, hyperthermia, hyperreflexia, diaphoresis, shivering, and tremor. The concomitant use of EXXUA with MAOIs is contraindicated. In addition, do not initiate EXXUA in a patient being treated with MAOIs such as linezolid or intravenous methylene blue. If it is necessary to initiate treatment with an MAOI such as linezolid or intravenous methylene blue in a patient taking EXXUA discontinue EXXUA before initiating treatment with the MAOI.
If concomitant use of EXXUA with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. Discontinue EXXUA and/or concomitant serotonergic drug immediately if the above symptoms occur and initiate supportive symptomatic treatment.
Activation of Mania or Hypomania
Antidepressant treatment can precipitate a manic, mixed, or hypomanic manic episode. The risk appears to be increased in patients with bipolar disorder or who have risk factors for bipolar disorder. Prior to initiating treatment with EXXUA, screen patients for a history of bipolar disorder and the presence of risk factors for bipolar disorder (e.g., family history of bipolar disorder, suicide, or depression). EXXUA is not approved for use in treating bipolar depression.
ADVERSE REACTIONS
Most common adverse reactions (incidence of ≥
The following adverse reactions are discussed in greater detail in other sections of the labeling:
Suicidal Thoughts and Behaviors in Adolescents and Young Adults
QT Prolongation
Serotonin Syndrome
Activation of Mania or Hypomania
To report SUSPECTED ADVERSE REACTIONS, contact Aytu BioPharma at 1-855-298-8246 or http://www.exxua.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
USE IN SPECIFIC POPULATIONS
Pregnancy
The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to
There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antidepressants, including EXXUA, during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Antidepressants at 1-866-961-2388 or visiting online at https://womensmentalhealth.org/research/pregnancyregistry/antidepressants/.
Lactation
There is no data on the presence of gepirone in human milk, the effects on the breastfed infant, or the effects on milk production. Gepirone is present in rat milk. When a drug is present in animal milk, it is likely that the drug will be present in human milk. There are reports of breastfed infants exposed to other serotonergic antidepressants experiencing irritability, restlessness, excessive somnolence, decreased feeding, and weight loss. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for EXXUA and any adverse effects on the breastfed infant from EXXUA or from the underlying maternal condition.
OVERDOSAGE
In clinical studies, cases of acute ingestions up to 454 mg (6.25 times the maximum recommended dose) of EXXUA alone or in combination with other drugs, were reported. Signs and symptoms reported with overdose of EXXUA at doses up to 454 mg included vomiting and transient incomplete bundle branch block; an unknown dose of EXXUA produced altered level of consciousness and a 60-second convulsion. No specific antidotes for EXXUA are known. Consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdose management recommendations.
Please see Full Prescribing Information for EXXUA.
Footnote 1
Aytu uses the term adjusted EBITDA, which is a term not defined under United States generally accepted accounting principles ("U.S. GAAP"). The Company uses this term because it is a widely accepted financial indicator utilized to analyze and compare companies on the basis of operating performance. The Company believes that presenting adjusted EBITDA by certain categories allows investors to evaluate the various performance of these categories. The Company's method of computation of adjusted EBITDA may or may not be comparable to other similarly titled measures used by other companies. The Company believes that net (loss) income is the performance measure calculated and presented in accordance with U.S. GAAP that is most directly comparable to adjusted EBITDA. See below for a reconciliation of net (loss) income to adjusted EBITDA.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended ("Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended ("Exchange Act"). All statements other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are generally written in the future tense and/or are preceded by words such as "may," "will," "should," "forecast," "could," "expect," "suggest," "believe," "estimate," "continue," "anticipate," "intend," "plan," or similar words, or the negatives of such terms or other variations on such terms or comparable terminology. All statements other than statements of historical facts contained in this presentation, are forward-looking statements. These statements are predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others, risks associated with: the Company's overall financial and operational performance, potential adverse changes to the Company's financial position or its business, the results of operations, strategy and plans, changes in capital markets and the ability of the Company to finance operations in the manner expected, risks relating to gaining market acceptance of its products, its partners performing their required activities, its anticipated future cash position, regulatory and compliance challenges and future events under current and potential future collaborations. The Company also refers you to (i) the risks described in "Risk Factors" in Part I, Item 1A of the Company's most recent Annual Report on Form 10‑K and in the other reports and documents it files with the United States Securities and Exchange Commission.
Contacts for Investors
Ryan Selhorn, Chief Financial Officer
Aytu BioPharma, Inc.
rselhorn@aytubio.com
Robert Blum
Lytham Partners
aytu@lythampartners.com
Aytu BioPharma, Inc.
Unaudited Consolidated Statements of Operations
(in thousands, except share and per share data)
Three Months Ended | ||||||||
March 31, | ||||||||
2026 | 2025 | |||||||
Net revenue | $ | 12,411 | $ | 18,452 | ||||
Cost of goods sold | 4,812 | 5,646 | ||||||
Gross profit | 7,599 | 12,806 | ||||||
Operating expenses: | ||||||||
Selling and marketing | 5,929 | 5,194 | ||||||
General and administrative | 4,973 | 4,109 | ||||||
Research and development | - | 162 | ||||||
Amortization of intangible assets | 761 | 920 | ||||||
Total operating expenses | 11,663 | 10,385 | ||||||
(Loss) income from operations | (4,064 | ) | 2,421 | |||||
Other income, net | 149 | 36 | ||||||
Interest expense | (436 | ) | (900 | ) | ||||
Derivative warrant liabilities (loss) gain | (1,257 | ) | 2,261 | |||||
(Loss) income from continuing operations before income tax expense | (5,608 | ) | 3,818 | |||||
Income tax (expense) benefit | (10 | ) | 122 | |||||
Net (loss) income from continuing operations | (5,618 | ) | 3,940 | |||||
Net income from discontinued operations, net of tax | - | 54 | ||||||
Net (loss) income | $ | (5,618 | ) | $ | 3,994 | |||
Basic weighted-average common shares outstanding | 10,511,583 | 6,134,634 | ||||||
Diluted weighted-average common shares outstanding | 10,511,583 | 8,204,453 | ||||||
Net (loss) income per share: | ||||||||
Basic - continuing operations | $ | (0.53 | ) | $ | 0.64 | |||
Diluted - continuing operations | $ | (0.53 | ) | $ | 0.20 | |||
Basic - discontinued operations, net of tax | $ | - | $ | 0.01 | ||||
Diluted - discontinued operations, net of tax | $ | - | $ | 0.01 | ||||
Basic - net (loss) income | $ | (0.53 | ) | $ | 0.65 | |||
Diluted - net (loss) income | $ | (0.53 | ) | $ | 0.21 | |||
Aytu BioPharma, Inc.
Unaudited Consolidated Balance Sheets
(in thousands, except share data)
March 31, | June 30, | |||||||
2026 | 2025 | |||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 26,715 | $ | 30,952 | ||||
Accounts receivable, net | 24,489 | 31,155 | ||||||
Inventories | 7,460 | 11,434 | ||||||
Prepaid expenses and other current assets | 8,662 | 5,638 | ||||||
Total current assets | 67,326 | 79,179 | ||||||
Non-current assets: | ||||||||
Property and equipment, net | 407 | 532 | ||||||
Operating lease right-of-use assets | 910 | 1,061 | ||||||
Intangible assets, net | 42,490 | 42,201 | ||||||
Other non-current assets | 556 | 1,204 | ||||||
Total non-current assets | 44,363 | 44,998 | ||||||
Total assets | $ | 111,689 | $ | 124,177 | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 13,214 | $ | 10,601 | ||||
Accrued liabilities | 34,270 | 38,164 | ||||||
Revolving credit facility | 10,411 | 9,063 | ||||||
Current portion of debt | 1,857 | 1,857 | ||||||
Other current liabilities | 220 | 3,379 | ||||||
Total current liabilities | 59,972 | 63,064 | ||||||
Non-current liabilities: | ||||||||
Debt, net of current portion | 9,549 | 10,895 | ||||||
Derivative warrant liabilities | 2,182 | 26,334 | ||||||
Other non-current liabilities | 4,843 | 4,918 | ||||||
Total non-current liabilities | 16,574 | 42,147 | ||||||
Stockholders' equity: | ||||||||
Preferred stock, par value | - | - | ||||||
Common stock, par value | 1 | 1 | ||||||
Additional paid-in capital | 382,914 | 352,500 | ||||||
Accumulated deficit | (347,772 | ) | (333,535 | ) | ||||
Total stockholders' equity | 35,143 | 18,966 | ||||||
Total liabilities and stockholders' equity | $ | 111,689 | $ | 124,177 | ||||
Aytu BioPharma, Inc.
Unaudited Reconciliation of Net (Loss) Income to Adjusted EBITDA
(in thousands)
Three Months Ended | ||||||||
March 31, | ||||||||
2026 | 2025 | |||||||
Net (loss) income - GAAP | $ | (5,618 | ) | $ | 3,994 | |||
Interest expense | 436 | 900 | ||||||
Income tax expense (benefit) | 10 | (122 | ) | |||||
Depreciation and amortization | 1,121 | 1,287 | ||||||
Stock-based compensation expense | 148 | 139 | ||||||
Other income, net | (149 | ) | (36 | ) | ||||
Derivative warrant liabilities loss (gain) | 1,257 | (2,261 | ) | |||||
Pipeline research and development costs | - | 96 | ||||||
Net income from discontinued operations, net of tax | - | (54 | ) | |||||
Adjusted EBITDA - non-GAAP | $ | (2,795 | ) | $ | 3,943 | |||
SOURCE: Aytu BioPharma, Inc.
View the original press release on ACCESS Newswire